For decades, governments have struggled with a legitimate challenge of keeping impaired drivers off the road while respecting the rights of lawful cannabis patients. Nobody disputes that driving while genuinely impaired is dangerous and should remain illegal. The real question is whether people who use prescribed cannabis as medicine should face arrest, prosecution, or loss of their licence simply because traces of THC remain in their body long after impairment has disappeared. The evidence increasingly suggests that current cannabis-driving laws often fail to distinguish between impairment and mere presence of THC, creating a system that can unfairly punish medical patients who are not actually unsafe drivers.
Unlike alcohol, cannabis behaves very differently in the human body. With alcohol, blood alcohol concentration (BAC) closely correlates with impairment. A person with a BAC of 0.08 is generally more impaired than someone with a BAC of 0.02. This relationship allows police and courts to use alcohol testing as a relatively reliable measure of driving impairment. Cannabis is different. Multiple studies have found that THC concentrations in blood, saliva, or oral fluid are often poor indicators of actual driving impairment. Researchers have repeatedly reported weak, inconsistent, or nonexistent correlations between THC levels and real-world driving performance. (PMC)
In fact, a 2024 study examining edible cannabis and driving found that driving impairment was not correlated with blood THC concentrations. (StratCann) This creates a major legal and scientific problem. A driver may test positive for THC despite being completely unimpaired at the time of driving.
One of the biggest flaws in many cannabis driving laws is the failure to account for tolerance. Prescription cannabis patients often use cannabis daily to manage conditions such as chronic pain, multiple sclerosis, epilepsy, PTSD, anxiety disorders, cancer-related symptoms, and more. As a result, these patients develop significant tolerance to THC. Tolerance means that the same amount of THC produces far fewer psychoactive effects than it would in a new or occasional user. Imagine a medical patient who has used prescribed cannabis every day for three years vs a recreational user who consumes cannabis once a month. If both have similar THC concentrations in their blood, their level of impairment may be dramatically different. The occasional user may experience significant intoxication, while the medical patient may experience little or no noticeable impairment due to tolerance.
Research has shown that frequent cannabis users can maintain detectable THC levels in their blood long after use and often show poor correlation between blood THC concentrations and impairment. THC can accumulate in body fat and slowly release back into the bloodstream, meaning a frequent user may test positive even when not impaired. (ScienceDirect) In other words, many medical patients may effectively be punished for their treatment regimen rather than their driving ability.
Many jurisdictions rely heavily on roadside saliva or oral fluid testing. The public often assumes these tests determine whether someone is impaired. They do not. What these tests generally detect is the presence of THC or cannabis metabolites, not whether the driver is actually incapable of driving safely. Several reviews have concluded that oral fluid tests cannot reliably determine impairment. (PMC)
A major review from researchers at the University of Sydney concluded that blood and oral fluid THC concentrations are relatively poor indicators of cannabis-induced impairment. (The University of Sydney)
Another analysis concluded that oral fluid tests should not be considered a valid indicator of cannabis impairment. (ScienceDirect)
This distinction matters enormously.
A test that answers the question:
"Has this person used cannabis recently?"
is not the same as a test that answers:
"Is this person impaired right now?"
Current roadside testing often addresses the first question while laws and prosecutions treat it as if it answers the second.
Research evaluating oral fluid testing devices found measurable rates of false positives and false negatives. One study reported false-positive rates of 5–10% and false-negative rates of 9–16%, while neither device met recommended standards for sensitivity, specificity, and accuracy. (PMC)
Systematic reviews have also found significant variability in the performance of roadside oral-fluid testing devices. (PMC)
That means drivers can potentially be flagged despite not meeting legal thresholds, missed despite recent use, subjected to further investigation based on imperfect screening technology.
When criminal penalties, license suspensions, employment consequences, and reputational damage are involved, these limitations should concern everyone.
Many governments have adopted "per se" THC laws that criminalize driving above a specific THC concentration. The intention is understandable. Policymakers wanted a simple numerical standard similar to alcohol laws. The problem is that cannabis science does not support such a straightforward comparison. Researchers have repeatedly noted that there is no universally accepted THC concentration that reliably indicates impairment across all individuals. (PMC) A blood THC concentration that may impair one driver could have little effect on another driver who uses cannabis regularly and has developed substantial tolerance. This is especially relevant for medical cannabis patients who may maintain residual THC levels even after any impairing effects have disappeared. (ScienceDirect)
Advocating for prescription cannabis patients does not mean endorsing impaired driving. Someone who is genuinely impaired by cannabis should not be behind the wheel. The same standard should apply to alcohol, prescription medications, illicit substances, fatigue, or any other condition that compromises driving ability. Public safety must remain the priority. However, public safety is best served by identifying actual impairment, not simply detecting traces of a legally prescribed medication. The goal should be to remove unsafe drivers from the road, not to criminalize patients who pose no greater risk than anyone else. A fair cannabis-driving policy would focus on impairment rather than mere THC detection. Potential reforms could include, greater reliance on evidence of actual driving impairment, better impairment assessment technologies., recognition of cannabis prescriptions, consideration of patient tolerance and frequency of use, scientific review of per se THC limits, independent confirmation of roadside screening results before penalties are imposed.
Emerging research is already exploring objective measures of impairment, including eye-tracking and cognitive-performance assessments, which may ultimately provide a more accurate picture of whether a driver is genuinely impaired. (arXiv)
Prescription cannabis patients deserve the same rights and protections afforded to people who take any other prescribed medication. They should never be given a free pass to drive while impaired, but neither should they live in fear of arrest simply because a roadside test detects residual THC from lawful medical treatment.
Until the law catches up with the science, many responsible prescription cannabis patients will continue to face an unfair choice between managing their health and risking criminal consequences for driving while perfectly capable of doing so safely.